Gyldenkerne C, Mortensen MB, Kahlert J, et al. 10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2023;82(16):1583–94.

Article  PubMed  Google Scholar 

Lukic N, Macvanin MT, Gluvic Z, Rizzo M, Radak D, Suri JS, Isenovic ER. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. Curr Med Chem. 2024;31(30):4781–806.

Article  PubMed  Google Scholar 

Soejima H, Ogawa H, Morimoto T, et al. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients. Heart Vessels. 2023Nov;38(11):1371–9.

Article  PubMed  Google Scholar 

Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447–61.

Article  CAS  PubMed  Google Scholar 

Zhang X, Zhao S, Huang Y, et al. Diabetes-Related Macrovascular Complications Are Associated With an Increased Risk of Diabetic Microvascular Complications: A Prospective Study of 1518 Patients With Type 1 Diabetes and 20 802 Patients With Type 2 Diabetes in the UK Biobank. J Am Heart Assoc. 2024Jun 4;13(11): e032626.

Article  PubMed  PubMed Central  Google Scholar 

Johansson C, Örtendahl L, Lind MM, et al. Diabetes, prediabetes, and atrial fibrillation-A population-based cohort study based on national and regional registers. J Intern Med. 2023;294(5):605–15.

Article  CAS  PubMed  Google Scholar 

Newman JD, O’Meara E, Böhm M, et al. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(9):932–50.

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34.

Article  CAS  PubMed  Google Scholar 

Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359–68.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–17.

Article  CAS  PubMed  Google Scholar 

Chan Y-H, Chao T-F, Chen S-W, et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol. 2022Jun 28;21(1):118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang C-Y, Yeh Y-H, Chan Y-H, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017Dec 19;16(1):159.

Article  PubMed  PubMed Central  Google Scholar 

Kim M, Ha KH, Lee J, et al. Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study. Korean Circ J. 2024;54(5):256–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharen Lee, Jiandong Zhou, Carlin Chang, et al. Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke outcomes.

Lee S, Zhou J, Leung KSK, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. Cardiovasc Drugs Ther. 2023Jun;37(3):561–9.

Article  CAS  PubMed  Google Scholar 

Li Y, Tang H, Guo Yi, et al. Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis. Front Pharmacol. 2024May;23(15):1379251.

Article  Google Scholar 

Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020 19(1):188.

Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2018;20(2):344–51.

Article  CAS  PubMed  Google Scholar 

Real J, Vlacho B, Ortega E, et al. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol. 2021Jul 9;20(1):139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood SJ, Bell JS, Magliano DJ, Shaw JE, Cesari M, Ilomaki J. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized. Front Pharmacol. 2022;13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li D, Liu Y, Hidru TH, et al. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. Front Endocrinol (Lausanne). 2021;12:619586.

Article  PubMed  PubMed Central  Google Scholar 

Lim J, Kwak S, Choi Y-J, et al. Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real-World Observation Using a Nationwide, Population-Based Cohort. J Am Heart Assoc. 2024Feb 6;13(3): e030552.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W-J, Chen X-Q, Ling-ling Xu, Li Y-Q, Luo B-H. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:130.

Article  PubMed  PubMed Central  Google Scholar 

AM Fawzy, JM Rivera‐Caravaca, P Underhill, L Fauchier, GYH Lip. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023 25(2): 602–610.

Li C-X, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS ONE. 2021;16(2): e0244689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–24.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Sarraju A, Spencer-Bonilla G, Rodriguez F, Mahaffey KW. Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Future Cardiol. 2021;17(1):39–48.

Article  CAS  PubMed  Google Scholar 

Soliman Y, Abuelazm M, Amer BE. Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis. Am J Cardiovasc Drugs. 2024;24(5):629–40.

Article  CAS  PubMed  PubMed Central  Google Scholar